December 17, 2018
Synthego – The Bench
CRISPR Clinical Trials: Will CRISPR Cure These Diseases?

September 07, 2018
Business Wire
CORRECTING and REPLACING CureDuchenne Ventures Commits $500,000 to 4D Molecular Therapeutics to Advance Next-Generation AAV Delivery of Gene Therapy

August 30, 2018
Wired Magazine

November 15, 2017
Capricor Therapeutics
Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Investigational Cell Therapy

November 08, 2017
Exonics Therapeutics
Exonics Therapeutics Raises $40 Million in Series A Financing

October 04, 2017
Capricor Therapeutics
Capricor Therapeutics Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at World Muscle Society International Congress

October 04, 2017
Catabasis Pharmaceuticals
Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD® Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial in First Half 2018

July 27, 2017
Sarepta Therapeutics
Sarepta Therapeutics Announces its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data in Nature Communications

June 22, 2017
Santhera Pharmaceuticals
Santhera’s Raxone® Receives First Positive EAMS Scientific Opinion from UK’s MHRA in Duchenne Muscular Dystrophy

Hike for Hope is operating under the HIKE FOR HOPE FOUNDATION INC
936 W Francis St., Aspen, CO. 81611
Tel: 970-925-6137,
Tax-exempt 501 (c)(3)
charitable organization.
Tax ID 20-3596738